Fengshen Kuo
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 23
- Cancer Immunotherapy and Biomarkers 18
- CAR-T cell therapy research 4
-
- Cancer Genomics and Diagnostics 8
- Co-authors
- Timothy An-thy Chan (19 shared papers)Luc G. T. Morris (14 shared papers)Nadeem Riaz (5 shared papers)Diego Chowell (4 shared papers)A. Ari Hakimi (17 shared papers)Naiyer A. Rizvi (2 shared papers)Vladimir Makarov (2 shared papers)Ruhong Zhou (2 shared papers)
- Journals
- Clinical Cancer Research (6 papers)Nature Communications (5 papers)Cancer Cell (4 papers)Nature Medicine (4 papers)Nature Genetics (3 papers)
- Partner nations
- United StatesGermanyIsrael
In The Last Decade
Fengshen Kuo
66 papers receiving 7.2k citations
Fengshen Kuo's Hit Papers
Peers
Comparison fields: 5 of 117
- Oncology 3.4k
- Immunology 2.1k
- Cancer Research 1.2k
- Pulmonary and Respiratory Medicine 1.5k
- Otorhinolaryngology 146
Countries citing papers authored by Fengshen Kuo
This map shows the geographic impact of Fengshen Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengshen Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengshen Kuo more than expected).
Fields of papers citing papers by Fengshen Kuo
This network shows the impact of papers produced by Fengshen Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengshen Kuo. The network helps show where Fengshen Kuo may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengshen Kuo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Hit paper breakdown → | 2017 | 1708 |
| 2 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 892 |
| 3 | Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response Hit paper breakdown → | 2019 | 429 |
| 4 | 2019 | 311 | |
| 5 | Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy Hit paper breakdown → | 2021 | 288 |
| 6 | 2003 | 230 | |
| 7 | 2020 | 224 | |
| 8 | 2019 | 222 | |
| 9 | 2018 | 221 | |
| 10 | 2021 | 200 | |
| 11 | 2019 | 183 | |
| 12 | 2020 | 169 | |
| 13 | 2020 | 168 | |
| 14 | 2020 | 155 | |
| 15 | 2022 | 148 | |
| 16 | 2019 | 143 | |
| 17 | 2018 | 135 | |
| 18 | 2019 | 124 | |
| 19 | 2018 | 122 | |
| 20 | 2020 | 113 |
About Fengshen Kuo
Fengshen Kuo is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Surgery, having authored 71 papers that have together received 7.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (18 papers), Renal cell carcinoma treatment (9 papers), Cancer Genomics and Diagnostics (8 papers), Immunotherapy and Immune Responses (8 papers), Bladder and Urothelial Cancer Treatments (8 papers), Salivary Gland Tumors Diagnosis and Treatment (6 papers), Ferroptosis and cancer prognosis (6 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Oncology (3.4k citations), Immunology (2.1k citations), Cancer Research (1.2k citations), Pulmonary and Respiratory Medicine (1.5k citations) and Otorhinolaryngology (146 citations). Fengshen Kuo has collaborated with scholars based in United States, Germany and Israel. Frequent co-authors include Timothy An-thy Chan, Luc G. T. Morris, Nadeem Riaz, Diego Chowell, A. Ari Hakimi, Naiyer A. Rizvi, Vladimir Makarov, Ruhong Zhou, Sviatoslav M. Kendall and Benjamin D. Greenbaum. Their work appears in journals such as Clinical Cancer Research, Nature Communications, Cancer Cell, Nature Medicine and Nature Genetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.